Nimvastid (Rivastigmine)

Rivastigmine reversibly blocks acetylcholinesterase and butyrylcholinesterase, the enzymes that degrade acetylcholine in the brain. By inhibiting these enzymes, it raises acetylcholine levels, enhancing cholinergic neurotransmission that is typically reduced in Alzheimer’s and Parkinson’s disease dementia.

The exact dose of Nimvastid is determined by the prescribing clinician based on the patient’s condition, tolerability, and response. Dose titration usually starts at a low level and is increased gradually, following the prescriber’s assessment and local prescribing guidelines.

Rivastigmine is classified as a pregnancy‑category C medication, meaning risk cannot be ruled out. It is generally not recommended for use during pregnancy or lactation unless the potential benefit justifies the potential risk. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To request Nimvastid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nimvastid (rivastigmine) belongs to the acetylcholinesterase inhibitor class, similar to donepezil and galantamine. Compared with donepezil, rivastigmine also inhibits butyrylcholinesterase, which may offer additional benefit in certain patients. However, its side‑effect profile, especially gastrointestinal symptoms, can be more pronounced, and dosing schedules differ.

Nimvastid should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or near heat sources.

Nimvastid is taken orally as a tablet. The tablet should be swallowed whole with a glass of water, with or without food, as directed by the prescriber. Patients should follow the dosing schedule provided and avoid crushing or chewing the tablet unless a specific formulation permits it.

Serious risks include severe gastrointestinal events such as persistent vomiting or bleeding, significant bradycardia that can lead to syncope, rare but severe skin reactions like Stevens‑Johnson syndrome, and hepatic enzyme elevations indicating possible liver injury. Patients should seek immediate medical attention if any of these occur.

Nimvastid is contraindicated in individuals with known hypersensitivity to rivastigmine or any excipients, severe hepatic impairment, or those taking other acetylcholinesterase inhibitors concurrently. Caution is also advised for patients with cardiac conduction disorders, uncontrolled asthma, or a history of severe gastrointestinal ulceration.